|
1
|
Tkachenko A. Hemocompatibility studies in nanotoxicology: Hemolysis or eryptosis? (A review). Toxicol In Vitro 2024; 98:105814. [PMID: 38582230 DOI: 10.1016/j.tiv.2024.105814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/13/2024] [Accepted: 04/03/2024] [Indexed: 04/08/2024]
Abstract
Hemocompatibility evaluation is an important step in nanotoxicological studies. It is generally accepted that nanomaterials promote lysis of erythrocytes, blood clotting, alter phagocytosis, and upregulate pro-inflammatory cytokines. However, there are no standardized guidelines for testing nanomaterials hemocompatibility despite the fact that nanomaterials enter the bloodstream and interact with blood cells. In this review, the current knowledge on the ability of nanomaterials to induce distinct cell death modalities of erythrocytes is highlighted primarily focusing on hemolysis and eryptosis. This review aims to summarize the molecular mechanisms underlying erythrotoxicity of nanomaterials and critically compare the sensitivity and efficiency of hemolysis or eryptosis assays for nanomaterials blood compatibility testing. The list of eryptosis-inducing nanomaterials is growing, but it is still difficult to generalize how physico-chemical properties of nanoparticles affect eryptosis degree and molecular mechanisms involved. Thus, another aim of this review is to raise the awareness of eryptosis as a nanotoxicological tool to encourage the corresponding studies. It is worthwhile to consider adding eryptosis to in vitro nanomaterials hemocompatibility testing protocols and guidelines.
Collapse
Affiliation(s)
- Anton Tkachenko
- BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 25250 Vestec, Czech Republic.
| |
Collapse
|
|
2
|
Zhao C, Pan B, Wang T, Yang H, Vance D, Li X, Zhao H, Hu X, Yang T, Chen Z, Hao L, Liu T, Wang Y. Advances in NIR-Responsive Natural Macromolecular Hydrogel Assembly Drugs for Cancer Treatment. Pharmaceutics 2023; 15:2729. [PMID: 38140070 PMCID: PMC10747500 DOI: 10.3390/pharmaceutics15122729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/28/2023] [Accepted: 12/01/2023] [Indexed: 12/24/2023] Open
Abstract
Cancer is a serious disease with an abnormal proliferation of organ tissues; it is characterized by malignant infiltration and growth that affects human life. Traditional cancer therapies such as resection, radiotherapy and chemotherapy have a low cure rate and often cause irreversible damage to the body. In recent years, since the traditional treatment of cancer is still very far from perfect, researchers have begun to focus on non-invasive near-infrared (NIR)-responsive natural macromolecular hydrogel assembly drugs (NIR-NMHADs). Due to their unique biocompatibility and extremely high drug encapsulation, coupling with the spatiotemporal controllability of NIR, synergistic photothermal therapy (PTT), photothermal therapy (PDT), chemotherapy (CT) and immunotherapy (IT) has created excellent effects and good prospects for cancer treatment. In addition, some emerging bioengineering technologies can also improve the effectiveness of drug delivery systems. This review will discuss the properties of NIR light, the NIR-functional hydrogels commonly used in current research, the cancer therapy corresponding to the materials encapsulated in them and the bioengineering technology that can assist drug delivery systems. The review provides a constructive reference for the optimization of NIR-NMHAD experimental ideas and its application to human body.
Collapse
Affiliation(s)
- Chenyu Zhao
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
- Department of Chemistry, School of Forensic Medicine, China Medical University, Shenyang 110122, China;
- Liaoning Province Key Laboratory of Forensic Bio-Evidence Sciences, Shenyang 110122, China
- Center of Forensic Investigation, China Medical University, Shenyang 110122, China
| | - Boyue Pan
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
- Department of Chemistry, School of Forensic Medicine, China Medical University, Shenyang 110122, China;
- Liaoning Province Key Laboratory of Forensic Bio-Evidence Sciences, Shenyang 110122, China
- Center of Forensic Investigation, China Medical University, Shenyang 110122, China
| | - Tianlin Wang
- Department of Biophysics, School of Intelligent Medicine, China Medical University, Shenyang 110122, China; (T.W.); (H.Y.)
| | - Huazhe Yang
- Department of Biophysics, School of Intelligent Medicine, China Medical University, Shenyang 110122, China; (T.W.); (H.Y.)
| | - David Vance
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
- School of Pharmacy, Queen’s University Belfast, Belfast BT7 1NN, UK
| | - Xiaojia Li
- Teaching Center for Basic Medical Experiment, China Medical University, Shenyang 110122, China; (X.L.); (H.Z.)
| | - Haiyang Zhao
- Teaching Center for Basic Medical Experiment, China Medical University, Shenyang 110122, China; (X.L.); (H.Z.)
| | - Xinru Hu
- The 1st Clinical Department, China Medical University, Shenyang 110122, China;
| | - Tianchang Yang
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
| | - Zihao Chen
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
| | - Liang Hao
- Department of Chemistry, School of Forensic Medicine, China Medical University, Shenyang 110122, China;
- Liaoning Province Key Laboratory of Forensic Bio-Evidence Sciences, Shenyang 110122, China
- Center of Forensic Investigation, China Medical University, Shenyang 110122, China
| | - Ting Liu
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
| | - Yang Wang
- China Medical University—The Queen’s University Belfast Joint College, China Medical University, Shenyang 110122, China; (C.Z.); (B.P.); (D.V.); (T.Y.); (Z.C.)
- Department of Chemistry, School of Forensic Medicine, China Medical University, Shenyang 110122, China;
- Liaoning Province Key Laboratory of Forensic Bio-Evidence Sciences, Shenyang 110122, China
- Center of Forensic Investigation, China Medical University, Shenyang 110122, China
| |
Collapse
|